CROI 2015 Program and Abstracts

Poster Sessions

O: HIV-Related and Non–HIV-Related Malignancies P-O1: HPV Infections and Cancers: Tuesday, 2/24/2015 P-O2: AIDS-Related Cancers: Lymphoma and KS: Wednesday, 2/25/2015 P-O3: Cancer and Cancer Risk in HIV Subpopulations and Lung Cancer: Thursday, 2/26/2015 P: Cardiovascular Complications of HIV Infection and Antiretroviral Therapy P-P1: Cardiovascular Disease Outcomes: Tuesday, 2/24/2015 P-P2: Dyslipidemia: Mediators and Treatment: Wednesday, 2/25/2015 P-P3: ART: Cardiovascular Risk and Hypertension: Wednesday, 2/25/2015 P-P7: Endothelial Functions and Cerebral Vasoreactivity: Tuesday, 2/24/2015 Q: Other Complications of HIV Infection and Antiretroviral Therapy P-Q1: Inflammation: Biomarkers and Relationship to Outcomes: Tuesday, 2/24/2015 P-Q2: Bone Metabolism and ART: Mechanisms and Outcomes: Tuesday, 2/24/2015 P-Q3: Bone Disease: Mechanisms of Bone Loss and Fracture Risk: Tuesday, 2/24/2015 P-Q4: Measuring Bone Density: Tuesday, 2/24/2015 P-Q5: FatWithout Borders: Metabolic Complications in Resource-Limited Settings: Wednesday, 2/25/2015 P-Q6: Aging: Frailty, Telomeres, and mtDNA: Tuesday, 2/24/2015 P-Q7: Diabetes and Other Endocrine Disorders: Tuesday, 2/24/2015 P-Q8: Renal Dysfunction: ART and Biomarkers: Thursday, 2/26/2015 P-Q9: Renal Transplantation: Long-Term Outcomes: Thursday, 2/26/2015 P-Q10: Pulmonary Disease: Thursday, 2/26/2015 P-Q11: Body Composition and Risk Factors for Abnormalities: Thursday, 2/26/2015 P-Q12: Complications: Liver DiseaseWithout Viral Hepatitis: Thursday, 2/26/2015 P-Q13: Depression and Alcohol Use Disorders: Thursday, 2/26/2015 R: Tuberculosis and Other Opportunistic Infections P-R1: Immune Reconstitution Inflammatory Syndrome in Opportunistic Infections: Tuesday, 2/24/2015 P-R2: T-Cell Responses to Tuberculosis Infection: Tuesday, 2/24/2015 P-R3: TB Diagnostic Challenges: Tuesday, 2/24/2015 P-R4: TB Adverse Events, Recurrence, and Mortality: Tuesday, 2/24/2015 P-R5: Cryptococcal Meningitis: Host Response, Treatment, and Outcomes: Thursday, 2/26/2015 P-R6: Syphilis and HIV Coinfection: Tuesday, 2/24/2015 P-R7: Opportunistic Infections: Odds and End Organs: Tuesday, 2/24/2015 S: HIV inWomen andWomen’s Health P-S1: Access and Engagement: Thursday, 2/26/2015 P-S2: Cervical Sampling, Shedding, and Outcomes: Tuesday, 2/24/2015 P-S3: Hormonal Contraception: Thursday, 2/26/2015 T: Maternal/Fetal HIV P-T1: How Fast? How Often? Achieving Viral Suppression in Pregnant and PostpartumWomen: Tuesday, 2/24/2015 P-T2: Rates and Risks of MTCT and HIV-Free Survival: Tuesday, 2/24/2015 P-T3: Option B+: Retention and Transmission: Tuesday, 2/24/2015 P-T4: Health Outcomes of HIV- and ARV-Exposed Infants, Children, and Youth: Thursday, 2/26/2015 P-T5: Coinfections Among HIV-Exposed Infants and Children: Thursday, 2/26/2015 P-T6: ART Adherence, Adverse Effects, and Retention Among PregnantWomen and Infants: Tuesday, 2/24/2015 P-T7: Pharmacokinetics and Safety of ART During Pregnancy: Tuesday, 2/24/2015 P-P4: What Predicts Risk for CVD in HIV? Tuesday, 2/24/2015 P-P5: Cardiovascular Risk Prediction: Wednesday, 2/25/2015 P-P6: Biomarkers and Atherosclerosis: Tuesday, 2/24/2015

P-T8: Planning and Preventing Pregnancy: Tuesday, 2/24/2015 P-T9: Mechanisms of MTCT and Maternal/Infant Health: Thursday, 2/26/2015 P-T10: Immune Mechanisms in MTCT: Tuesday, 2/24/2015 P-T11: PMTCT-Associated Drug Resistance inWomen and Infants: Tuesday, 2/24/2015 U: Pediatrics and Adolescents P-U1: HIV Diagnosis in Infants and Children: Tuesday, 2/24/2015 P-U2: Early ART and HIV Persistence: Tuesday, 2/24/2015 P-U3: Treatment Outcomes Among Children and YouthWith HIV: Wednesday, 2/25/2015 P-U4: Treatment and Monitoring Strategies in Children: Wednesday, 2/25/2015 P-U5: Determinants of Disease Progression in Children: Tuesday, 2/24/2015 P-U6: Complications of HIV and ART: Pulmonary and Cardiovascular Outcomes: Thursday, 2/26/2015 P-U7: Complications of HIV and ART: Bones, Brains, and Kidneys: Thursday, 2/26/2015 P-U8: Tuberculosis and Other Coinfections in ChildrenWith HIV: Wednesday, 2/25/2015 P-U9: Responses to Vaccines in Children: Tuesday, 2/24/2015 P-U10: Pharmacokinetics, Safety, and Efficacy of ART in Children and Youth: Tuesday, 2/24/2015 V: Prevention and Intervention Studies P-V1: Postexposure Prophylaxis (PEP): Wednesday, 2/25/2015 P-V2: PrEP and Microbicide Challenge: Thursday, 2/26/2015 P-V3: PrEP: Uptake: Tuesday, 2/24/2015 P-V4: PrEP: Measures and Correlates of Adherence: Tuesday, 2/24/2015 P-V5: PrEP: Evaluating Potential Harm: Wednesday, 2/25/2015 P-V6: HIV Prevention, Miscellaneous: Thursday, 2/26/2015 W: Epidemiology P-W1: HIV Testing and the Continuum of Care in the IndustrializedWorld: Tuesday, 2/24/2015 P-W2: HIV Testing and the Continuum of Care in the DevelopingWorld: Tuesday, 2/24/2015 P-W3: Risk Factors for Transmission in MSM: Wednesday, 2/25/2015 P-W4: Transmission Through Needles and Heterosexual Contact: Wednesday, 2/25/2015 P-W5: Incidence and Prevalence of HIV Infection, Including Acute HIV: Thursday, 2/26/2015 P-W6: Disease Progression, Morbidity, and Mortality: Thursday, 2/26/2015 P-W7: HIV Stigma: Thursday, 2/26/2015 P-W8: Serosorting and Seroadaptive Behavior: What’s Your Position? Thursday, 2/26/2015 X: Health Care Delivery and Health Systems P-X1: Paying for Care: Tuesday, 2/24/2015 P-X2: Linkage to and Retention in Care: Wednesday, 2/25/2015 P-X3: Guidelines and Their Implementation: Thursday, 2/26/2015 Y: Implementation Science P-Y1: Male Circumcision: Risk, Innovation, and Scale-Up: Thursday, 2/26/2015 P-Y2: Linkage to Care and ART Initiation: Wednesday, 2/25/2015 P-Y3: HIV Testing: Innovations and Scale-Up: Wednesday, 2/25/2015 Z: Population and Economic Modeling P-Z1: Costs and Cost Effectiveness: Tuesday, 2/24/2015 P-Z2: Modeling HIV Epidemiology: Wednesday, 2/25/2015 P-Z3: Modeling the Impact of HIV Interventions: Thursday, 2/26/2015

Poster Sessions

23

CROI 2015